



NDA 203214/S-24
NDA 208246/S-10

SUPPLEMENT APPROVAL

PF PRISM C.V.
c/o Pfizer Inc.
Attention: Gary F. Perry
Director, Pfizer Global Regulatory Affairs
445 Eastern Point Road
Groton, PA 06340

Dear Mr. Perry:

Please refer to your supplemental new drug applications (sNDAs) dated June 7, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for XELJANZ (tofacitinib) and XELJANZ XR (tofacitinib) tablets.

We also refer to our letter dated May 9, 2019, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for XELJANZ (tofacitinib). This information pertains to the risk of thrombosis, pulmonary embolism, and all-cause mortality among rheumatoid arthritis (RA) patients taking tofacitinib 10 mg twice daily (BID) relative to those taking either tofacitinib 5 mg twice daily or TNF blockers in the post-marketing requirement (PMR) Study A 3921133.

These supplemental new drug applications provide for revisions to the labeling for XELJANZ (tofacitinib) and XELJANZ XL (tofacitinib) consistent with our May 9, 2019 letter.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

We note that your July 23, 2019, submissions include final printed labeling (FPL) for your Prescribing Information, and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this FPL is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling Prescribing Information, and Medication Guide, with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 203214/S-024

NDA 208246/S-010

Page 3

If you have any questions, call Kelly Richards, Senior Regulatory Project Manager, at (240) 402-4276.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOYCE A KORVICK
07/25/2019 05:10:03 PM